JP2012533595A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012533595A5 JP2012533595A5 JP2012521008A JP2012521008A JP2012533595A5 JP 2012533595 A5 JP2012533595 A5 JP 2012533595A5 JP 2012521008 A JP2012521008 A JP 2012521008A JP 2012521008 A JP2012521008 A JP 2012521008A JP 2012533595 A5 JP2012533595 A5 JP 2012533595A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- beta
- adrenergic receptor
- receptor agonist
- dosage form
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 9
- 239000000048 adrenergic agonist Substances 0.000 claims 7
- 102000016966 beta-2 Adrenergic Receptors Human genes 0.000 claims 7
- 108010014499 beta-2 Adrenergic Receptors Proteins 0.000 claims 7
- 239000002552 dosage form Substances 0.000 claims 4
- XWTYSIMOBUGWOL-UHFFFAOYSA-N Bricaril Chemical group CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 claims 3
- 230000035832 Lag time Effects 0.000 claims 3
- 230000035648 Lag-time Effects 0.000 claims 3
- 238000000338 in vitro Methods 0.000 claims 3
- 230000035839 C max Effects 0.000 claims 2
- 229960005105 Terbutaline Sulfate Drugs 0.000 claims 2
- 238000004090 dissolution Methods 0.000 claims 2
- 239000012530 fluid Substances 0.000 claims 2
- 230000000968 intestinal Effects 0.000 claims 2
- 235000012054 meals Nutrition 0.000 claims 2
- 230000036470 plasma concentration Effects 0.000 claims 2
- 230000036888 Average AUC Effects 0.000 claims 1
- 206010020993 Hypoglycaemia Diseases 0.000 claims 1
- 230000037098 T max Effects 0.000 claims 1
- 229960000195 Terbutaline Drugs 0.000 claims 1
- 230000002218 hypoglycaemic Effects 0.000 claims 1
- 230000000422 nocturnal Effects 0.000 claims 1
- 239000006186 oral dosage form Substances 0.000 claims 1
- 239000008363 phosphate buffer Substances 0.000 claims 1
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0912646.7A GB0912646D0 (en) | 2009-07-21 | 2009-07-21 | Improvements in or relating to organic compounds |
GB0912646.7 | 2009-07-21 | ||
PCT/EP2010/060326 WO2011009818A1 (en) | 2009-07-21 | 2010-07-16 | Beta 2 adrenergic receptor agonists such as terbutaline for use in the treatment of nocturnal hypoglycemia |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2012533595A JP2012533595A (ja) | 2012-12-27 |
JP2012533595A5 true JP2012533595A5 (ru) | 2013-09-05 |
JP6021641B2 JP6021641B2 (ja) | 2016-11-09 |
Family
ID=41058278
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012521008A Expired - Fee Related JP6021641B2 (ja) | 2009-07-21 | 2010-07-16 | 夜間低血糖症の治療にて用いるためのテルブタリンなどのベータ2アドレナリン作動性受容体アゴニスト |
Country Status (6)
Country | Link |
---|---|
US (1) | US8697755B2 (ru) |
EP (1) | EP2456430B1 (ru) |
JP (1) | JP6021641B2 (ru) |
ES (1) | ES2616322T3 (ru) |
GB (1) | GB0912646D0 (ru) |
WO (1) | WO2011009818A1 (ru) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8980894B2 (en) | 2004-03-25 | 2015-03-17 | Boehringer Ingelheim Vetmedica Gmbh | Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure |
EP1579862A1 (en) | 2004-03-25 | 2005-09-28 | Boehringer Ingelheim Vetmedica Gmbh | Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure |
EP1920785A1 (en) | 2006-11-07 | 2008-05-14 | Boehringer Ingelheim Vetmedica Gmbh | Liquid preparation comprising a complex of pimobendan and cyclodextrin |
EP2825159B1 (en) | 2012-03-15 | 2022-06-22 | Boehringer Ingelheim Vetmedica GmbH | Pharmaceutical tablet formulation for the veterinary medical sector, method of production and use thereof |
GB201218012D0 (en) * | 2012-10-08 | 2012-11-21 | Jagotec Ag | Dosage forms |
ES2860526T3 (es) | 2013-07-19 | 2021-10-05 | Boehringer Ingelheim Vetmedica Gmbh | Derivados de ciclodextrina eterificada conservados que contienen una composición farmacéutica acuosa líquida |
PL2925305T3 (pl) | 2013-12-04 | 2017-07-31 | Boehringer Ingelheim Vetmedica Gmbh | Ulepszone kompozycje farmaceutyczne pimobendanu |
US10537570B2 (en) | 2016-04-06 | 2020-01-21 | Boehringer Ingelheim Vetmedica Gmbh | Use of pimobendan for the reduction of heart size and/or the delay of onset of clinical symptoms in patients with asymptomatic heart failure due to mitral valve disease |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19809719A1 (de) * | 1998-03-06 | 1999-09-09 | Roehm Gmbh | Wäßrige Dispersion geeignet zur Herstellung von Überzugs- und Bindemitteln für feste orale Arzneiformen |
EP2319584A1 (en) * | 2002-08-29 | 2011-05-11 | Cipla Ltd. | Pharmaceutical products and compositions comprising salmeterol, ciclesonide and tiotropium |
-
2009
- 2009-07-21 GB GBGB0912646.7A patent/GB0912646D0/en not_active Ceased
-
2010
- 2010-07-16 EP EP10731762.0A patent/EP2456430B1/en not_active Not-in-force
- 2010-07-16 US US13/384,388 patent/US8697755B2/en active Active
- 2010-07-16 ES ES10731762.0T patent/ES2616322T3/es active Active
- 2010-07-16 JP JP2012521008A patent/JP6021641B2/ja not_active Expired - Fee Related
- 2010-07-16 WO PCT/EP2010/060326 patent/WO2011009818A1/en active Application Filing
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2012533595A5 (ru) | ||
RU2404750C2 (ru) | Композиция, содержащая основу или покрытие для замедленного высвобождения и антагонист nmda рецептора, способ введения такого nmda антагониста субъекту | |
US11602522B2 (en) | Secnidazole for use in the treatment of sexually transmitted infection | |
JP2008543936A5 (ru) | ||
JP2015531400A5 (ru) | ||
WO2011160136A3 (en) | Progesterone containing oral dosage forms and related methods | |
JP2013529665A5 (ru) | ||
RU2011110765A (ru) | Фармацевтическая композиция энтакапона или его солей пролонгрированного высвобождения | |
RU2012118668A (ru) | Комбинированная терапия с использованием агониста бета 3 адренергического рецептора и антимускаринового средства | |
JP2007529564A5 (ru) | ||
JP2019502741A5 (ru) | ||
JP2013528654A (ja) | インフルエンザ、一般的な感冒および炎症の治療におけるレボセチリジンおよびモンテルカストの使用 | |
JP2005528430A5 (ru) | ||
CN104758268A (zh) | 一种琥珀酸呋罗曲坦片及其制备方法 | |
JP2019218379A5 (ru) | ||
AR084093A1 (es) | Metodo para tratar los atracones o la ingesta compulsiva de alimentos; uso de buproprion y naltrexona para preparar un medicamento para dichos metodos, y composicion farmaceutica | |
JP2009522294A5 (ru) | ||
WO2008122190A1 (fr) | Composition comprenant de la l-carnitine ou ses dérivés et son utilisation | |
RU2017127509A (ru) | Композиции и способы для улучшенного мышечного метаболизма | |
RU2018104691A (ru) | Композиции с модифицированным высвобождением ницерголина | |
TWI482632B (zh) | 醫藥用載體及使用該載體的藥物結構 | |
WO2021132302A1 (ja) | 透析移行又は腎死の抑制のための薬剤 | |
JP2019535830A5 (ru) | ||
TW201803558A (zh) | 腸內環境改善劑 | |
JP2009507850A5 (ru) |